Tirzepatide + Semaglutide
Compounded tirzepatide with semaglutide as a sterile injectable. May be considered when both incretin mechanisms are desired; each has separate weight-management evidence with diet and activity, without established superior efficacy versus either alone.1234
Compounding required for medical necessity.
- Active ingredients
- Tirzepatide / Semaglutide
- Form
- Injection
- Route
- Subcutaneous
Are you a prescriber?
Download a compounding order form for this medication with dose options and packaging choices.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. In SURMOUNT-1, once-weekly tirzepatide produced substantial, sustained weight reduction versus placebo alongside lifestyle intervention.1 Approved tirzepatide labeling describes use with a reduced-calorie diet and increased physical activity, and carries a boxed warning regarding thyroid C-cell tumors in rodents.2
Semaglutide is a GLP-1 receptor agonist. In STEP 1, once-weekly semaglutide plus lifestyle intervention produced sustained, clinically relevant weight loss versus placebo in adults with overweight or obesity.3 Approved semaglutide labeling similarly describes use with diet and activity and includes a boxed warning about thyroid C-cell tumors in rodents.4
This catalog entry is a compounded combination of tirzepatide and semaglutide prepared for patient-specific prescriptions when medically necessary. Combining two incretin-pathway agents is not an FDA-approved regimen, and published trials of each drug alone do not establish that using them together is safer or more effective than either medicine alone. Do not assume additive or synergistic benefit.
This sterile injectable is not an FDA-approved finished drug product. Your clinician sets dose, titration, and monitoring for both components. Common class-related effects can include nausea, vomiting, diarrhea, constipation, and decreased appetite. Discuss personal or family history of medullary thyroid carcinoma or MEN2, pancreatitis risk, and other contraindications before use.
References
- Jastreboff AM et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387, 205-216
“In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight.”
- U.S. Food and Drug Administration (2025). ZEPBOUND (tirzepatide) injection, for subcutaneous use — Prescribing Information. FDA Prescribing Information
- Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384, 989-1002
“In participants with overweight or obesity, 2.4 mg of semaglutide once weekly plus lifestyle intervention was associated with sustained, clinically relevant reduction in body weight.”
- U.S. Food and Drug Administration (2025). WEGOVY (semaglutide) injection, for subcutaneous use — Prescribing Information. FDA Prescribing Information